Subsequent Events

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

10. Subsequent Events

 

Bio-Path entered into an agreement for drug substance manufacture of four additional batches of final drug product for testing.  In addition, the Company entered into an agreement with its drug substance manufacturer for three additional batches of antisense drug substance for use in the final drug product. The Company also entered into an agreement with a contract research organization for initiation of clinical trial services. In total, these projects will require Bio-Path to pay approximately $1,625,000 over a twelve month period.